ABSTRACT
Objective: This study investigated the association between use of sedatives in terminal cancer patients near death who were receiving home care and the home care period. Methods: We conducted a retrospective review of the medical records for 1032 cancer patients who received home palliative care from 17 specialized home care clinics between June and November 2013. We checked the use of sedatives within 48 hours before death at home, and we compared the home care period between patients with and without sedation. Results: The sedatives used were diazepam (n, %: 100, 52%), flunitrazepam (29, 15%), bromazepam (27, 14%), midazolam (26, 13%), and phenobarbital (20, 10%). The median home care period (median [quartiles]) was 26 [13, 63] days and 25 [10, 64] days (Adj p=0.79) for the patients with and without sedatives, respectively. Conclusion: Among terminal cancer patients near death receiving home care, 24% were administered sedatives, with more than half of those patients receiving diazepam. There was no association between use of sedatives and the home care period.
ABSTRACT
Purpose: This study was performed to compare the characteristics of home palliative care for elderly patients with cancer between age groups. Methods: The clinical records of 1,032 patients with cancer who received home medical care from June to November 2013 were reviewed retrospectively. Patients were classified as non-elderly (<65 years old), young-old (65-74 years), old-old (75-84 years), or oldest-old (≥85 years), and these groups were compared with respect to demographic characteristics, patient/family problems, outcomes, and medical care and services provided. Results: There was a higher percentage of patients with no caregiver in the oldest-old group than in the other groups (18%, p=0.014), while the young-old and oldest-old groups had a higher percentage of problems related to caregiving such as caregiver burden or absence of a caregiver (32% and 33%, p=0.002, respectively). In addition, the percentage of patients who required visiting nurses and care was higher in the old-old group (86% and 30%, respectively) and oldest-old group (89% and 35%, respectively) compared with the other two groups. Conclusion: Problems related to caregiving, such as caregiver burden or absence of a caregiver, were greater in the old-old and oldest-old groups, and a higher percentage of patients required visiting nurses and care in those two groups.
ABSTRACT
Purpose: This study investigated the current state of medical care and palliative care provided at home and the factors influencing death at home for terminally ill cancer patients living in single-person households. Methods: We conducted a retrospective questionnaire study of 1032 cancer patients living in single-person households who received home palliative care from 17 specialized home care clinics and finished home care between June and November 2013. We compared patient background factors, outcomes, home care services, and medical care between these patients and others not living in single-person households to investigate factors influencing death at home. Results: Compared with patients not living in single-person households, the patients living in single-person households were older, had a better performance status at initiation of home palliative care, showed a lower preference for dying at home, and received more frequent social hospitalization. Among the subjects from single-person households, factors influencing death at home were a family preference for dying at home (odds ratio (OR)=14.0), poor performance status at initiation of home palliative care (OR=4.0), and no hospitalization during home palliative care (OR=16.6). Conclusion: We found that death at home for terminally ill cancer patients living in single-person households and receiving home medical care and palliative care was influenced by family preference, the performance status at initiation of home palliative care, and hospitalization during home palliative care.
ABSTRACT
<b>Purpose and Methods</b>: In the WHO guidelines on the management of cancer pain, global standard-dose acetaminophen (APAP) is described as a first-line drug, but there have been few studies comparing the efficacy and safety of APAP with other options in Japan. We retrospectively studied the efficacy and safety of global standard-dose APAP in the management of cancer pain, by comparing 182 patients treated with global standard-dose APAP (1,800-2,400 mg/day) (APAP group) and 86 patients treated with NSAIDs (NSAIDs group) at our clinic. <b>Results</b>: As the result, the management of cancer pain was comparable between the APAP group and the NSAIDs group. Despite the lack of sufficient investigation of concomitant drug such as opioids, etc., global standard-dose APAP was not inferior to NSAIDs in terms of efficacy as a non-opioid analgesic for the treatment of cancer pain. When we compared safety between the APAP group and the NSAIDs group, the incidence of nausea was significantly lower in the APAP group (<i>p</i><0.01), while the percentage of patients with AST/ALT levels 2.5 times higher than at baseline was comparable in the 2 groups. <b>Conclusion</b>: Based on the above efficacy and safety results, global standard-dose APAP was concluded to be a useful non-opioid analgesic option for the treatment of cancer pain in Japan. Palliat Care Res 2011; 6(2): 133-142